Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
DiaMedica Therapeutics
(NASDAQ:DMAC)
Intraday
$2.61
0.19
[7.85%]
After-Hours
$2.61
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$2.61
0.19
[7.85%]
At close: Apr 17
$2.61
0
[0.00%]
PreMarket: 4:22PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for DiaMedica Therapeutics Stock (NASDAQ:DMAC)
DiaMedica Therapeutics Stock (NASDAQ: DMAC)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 17, 2024
DiaMedica Therapeutics Doses First Patient Relaunch Of Pivotal Phase 2/3 ReMEDy2 Trial Of DM199 For Acute Ischemic Stroke
Benzinga Newsdesk
-
6 days ago
Thursday, March 21, 2024
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $8
Benzinga Newsdesk
-
Mar 21, 2024, 2:31PM
Oppenheimer Reiterates Outperform on DiaMedica Therapeutics, Lowers Price Target to $6
Benzinga Newsdesk
-
Mar 21, 2024, 8:43AM
Tuesday, March 19, 2024
Recap: DiaMedica Therapeutics Q4 Earnings
Benzinga Insights
-
Mar 19, 2024, 5:25PM
DiaMedica Therapeutics FY23 EPS $(0.60) Vs $(0.52) YoY; $53M Cash With Runway To 2026
Benzinga Newsdesk
-
Mar 19, 2024, 4:31PM
Monday, November 13, 2023
DiaMedica Therapeutics Q3 EPS $(0.12) Beats $(0.13) Estimate
Benzinga Newsdesk
-
Nov 13, 2023, 4:57PM
Earnings Scheduled For November 13, 2023
Benzinga Insights
-
Nov 13, 2023, 6:40AM
Friday, November 10, 2023
Earnings Outlook For DiaMedica Therapeutics
Benzinga Insights
-
Nov 10, 2023, 12:02PM
Monday, August 14, 2023
DiaMedica Therapeutics Q2 EPS $(0.16) Beats $(0.18) Estimate
Benzinga Newsdesk
-
Aug 14, 2023, 4:48PM
Earnings Scheduled For August 14, 2023
Benzinga Insights
-
Aug 14, 2023, 6:45AM
Thursday, June 22, 2023
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Benzinga Insights
-
Jun 22, 2023, 11:02AM
Oppenheimer Upgrades DiaMedica Therapeutics to Outperform, Announces $7 Price Target
Benzinga Newsdesk
-
Jun 22, 2023, 7:16AM
Wednesday, June 21, 2023
DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199
Nabaparna Bhattacharya
-
Jun 21, 2023, 11:40AM
DiaMedica Therapeutics Announces $37.5M Private Placement Of 11,011,406 Common Shares At A Purchase Price Of $3.40/Share
Happy Mohamed
-
Jun 21, 2023, 8:42AM
DiaMedica Therapeutics Announces That The FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
Happy Mohamed
-
Jun 21, 2023, 8:16AM
Monday, May 22, 2023
Diamedica Therapeutics Included In Response To FDA Is Protocol Amendment To Incorporate Reduced Dose For Intravenous Administration Of DM199
Benzinga Newsdesk
-
May 22, 2023, 5:18PM
Filed On May 19, DiaMedica Therapeutics A Complete Clinical Hold Response With FDA For Clinical Hold On A Phase 2/3 Clinical Trial Of DM199; Response With FDA Requesting Clinical Hold Imposed On Phase 2/3 Clinical Trial Of DM199 For AIS Be Lifted
Benzinga Newsdesk
-
May 22, 2023, 5:17PM
Monday, May 15, 2023
DiaMedica Therapeutics Q1 EPS $(0.20) Misses $(0.16) Estimate
Benzinga Newsdesk
-
May 15, 2023, 4:32PM
Earnings Scheduled For May 15, 2023
Benzinga Insights
-
May 15, 2023, 5:32AM
Friday, May 12, 2023
Earnings Preview: DiaMedica Therapeutics
Benzinga Insights
-
May 12, 2023, 11:01AM
Tuesday, March 28, 2023
DiaMedica Therapeutics FY22 EPS $(0.52)
Michael Horton
-
Mar 28, 2023, 4:36PM
DiaMedica Therapeutics Provides A Business Update And Announces FY22 Financial Results; DiaMedica Reported Total Cash, Cash Equivalents And Investments Of $33.5M
Happy Mohamed
-
Mar 28, 2023, 4:34PM
Earnings Scheduled For March 28, 2023
Benzinga Insights
-
Mar 28, 2023, 6:38AM
Monday, March 27, 2023
DiaMedica Therapeutics's Earnings Outlook
Benzinga Insights
-
Mar 27, 2023, 12:02PM
Friday, December 02, 2022
$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying
Lisa Levin
-
Dec 2, 2022, 8:43AM
Wednesday, November 09, 2022
DiaMedica Therapeutics Q3 EPS $(0.12) Up From $(0.18) YoY
Benzinga Newsdesk
-
Nov 9, 2022, 5:09PM
Monday, November 07, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Nov 7, 2022, 12:47PM
Friday, October 28, 2022
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Lisa Levin
-
Oct 28, 2022, 4:57AM
Friday, October 07, 2022
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
Lisa Levin
-
Oct 7, 2022, 6:29AM
Thursday, October 06, 2022
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Oct 6, 2022, 12:41PM
Wednesday, August 10, 2022
DiaMedica Therapeutics: Q2 Earnings Insights
Benzinga Insights
-
Aug 10, 2022, 11:28PM
DiaMedica Therapeutics Q2 EPS $(0.13) Beats $(0.18) Estimate
Michael Horton
-
Aug 10, 2022, 5:21PM
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Vandana Singh
-
Aug 10, 2022, 11:33AM
Earnings Scheduled For August 10, 2022
Benzinga Insights
-
Aug 10, 2022, 5:33AM
Tuesday, August 09, 2022
DiaMedica Therapeutics Earnings Preview
Benzinga Insights
-
Aug 9, 2022, 12:18PM
Friday, July 22, 2022
3 Penny Stocks Insiders Are Buying: DiaMedica Therapeutics, Troika Media And More
Lisa Levin
-
Jul 22, 2022, 6:47AM
Friday, July 08, 2022
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
Lisa Levin
-
Jul 8, 2022, 4:15AM
Thursday, July 07, 2022
Ten Stocks Trending on Discord for Thursday July 7, 2022: TSLA, AMZN, CTMX, AAPL, GME, RGS, DMAC, JAGX, META, TTOO
Charles Gross
-
Jul 7, 2022, 3:41PM
Nasdaq Surges 250 Points; Crude Oil Rises Sharply
Lisa Levin
-
Jul 7, 2022, 3:01PM
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Jul 7, 2022, 12:12PM
Dow Jumps More Than 200 Points; Samsung Sees This Much Surge In Quarterly Revenue
Lisa Levin
-
Jul 7, 2022, 12:11PM
This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Jul 7, 2022, 12:02PM
Why U.S. Stocks Are Trading Higher After Rise In Jobless Claims
Lisa Levin
-
Jul 7, 2022, 10:23AM
Lake Street Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $8
Benzinga Newsdesk
-
Jul 7, 2022, 10:12AM
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Benzinga Insights
-
Jul 7, 2022, 10:04AM
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Vandana Singh
-
Jul 7, 2022, 10:03AM
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $12
Benzinga Newsdesk
-
Jul 7, 2022, 10:03AM
DiaMedica Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on its Phase 2/3 ReMEDy2 trial for DM199.
Benzinga Newsdesk
-
Jul 7, 2022, 9:46AM
Oppenheimer Downgrades DiaMedica Therapeutics to Perform
Benzinga Newsdesk
-
Jul 7, 2022, 9:15AM
FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why
Vandana Singh
-
Jul 7, 2022, 7:37AM
Show more